Aug 4, 2017

“Pharma bro” Shkreli convicted

Richard Drew / AP

Martin Shkreli — the former hedge-fund manager who became infamous after raising the price of a life-saving drug by more than 5,000% — was found guilty Friday of misleading investors, according to the Associated Press. The charges on which Shkreli was convicted Friday are unrelated to his drug-pricing scandal.

The back story: Shkreli rose to national notoriety after he bought the rights to the drug Daraprim, which had been on the market for years, and raised the price from $13.50 per pill to $750. He was hauled before Congress and became an easy target in the national uproar over high drug prices.

Why it doesn't matter: Daraprim still costs $750.

Go deeper

Rashaan Ayesh

Q&A: Minimizing your coronavirus risk

Illustration: Aïda Amer/Axios

As the coronavirus continues to spread throughout the U.S., Axios is answering readers' questions about the pandemic — how it spreads, who's at risk, and what you can do to stay safe.

What's new: This week, we answer five questions on smokers' vulnerability, food safety, visiting older parents, hair cut needs, and rural vs. urban impact.

To the answers22 mins ago - Health

Alison Snyder, Eileen Drage O'Reilly

The other coronavirus test we need

Illustration: Sarah Grillo/Axios

Researchers are racing to develop tests that detect whether someone may have developed immunity to the coronavirus, which could help society return to normal faster.

Why it matters: These tests could help people know if they are able to go back to work, as well as aid researchers in tracking the scale and death rate of the disease — key data for current and future pandemic policies.

Go deeper25 mins ago - Health

Sam Baker

What the U.S. can learn from other countries in the coronavirus fight

Data: The Center for Systems Science and Engineering at Johns Hopkins; Note: Cases are shown on a logarithmic scale; Chart: Naema Ahmed/Axios

The countries that have most successfully fended off the novel coronavirus have mainly done it with a combination of new technology and old-school principles.

Why it matters: There's a lot the U.S. can learn from the way other countries have handled this global pandemic — although we may not be able to apply those lessons as quickly as we'd like.

Go deeper28 mins ago - Health